Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20

While not perfect, the latest Phase II data for the stromal depleting agent PEGPH20 give cause for optimism for hyaluronan as a biomarker in pancreatic cancer and for Halozyme's Phase III strategy.

Cancer-cells-pink-color_1200x675

The latest Phase II data for Halozyme Therapeutics Inc.'s stromal depleting agent PEGPH20 lend some support for the use of one of the first biomarkers to emerge in pancreatic cancer – hyaluronan – as well as company's Phase III strategy, though the supportive results were not perfect.

The company reported updated results on Jan. 5 from the open-label HALO 202 Phase II study, which evaluated PEGPH20 in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category